50- Physician-Investor Series: Farzad Soleimani, MD (1984 Ventures)

Episode 50 September 11, 2023 00:47:40
50- Physician-Investor Series: Farzad Soleimani, MD (1984 Ventures)
Physicians Off The Beaten Path
50- Physician-Investor Series: Farzad Soleimani, MD (1984 Ventures)

Sep 11 2023 | 00:47:40


Hosted By

Alexey Youssef Shad Faraz

Show Notes

Dive into a seasoned venture capitalist's mind as they look at today's landscape! Dr. Farzad Soleimani is sharing valuable insights on:

Farzad is the Healthcare Partner at 1984 Ventures, having seeded companies such as Trusted Health, Deep Scribe, Health Note, and Signos. He is the founder of eTherapi, a pioneering telemedicine company, and the founding co-director of the Texas Medical Center Biodesign Innovation Program. He started his investing career at MohrDavidow Ventures and continued to work at a number of innovation startups, such as Pocket Naloxone, Hansen Medical, and IGAN Biosciences.

Farzad completed his residency training at Baylor and earned his MBA, MD, MS, and BS from Stanford University. He is on faculty at Baylor Medical School, Rice Business School, and Rice Bioengineering Department.

We volunteer our time and money to make this content freely available – if you enjoy our content and find it helpful, you can support us by buying us a coffee here!

Other Episodes

Episode 12

December 01, 2021 00:49:32
Episode Cover

12- Physician-Entrepreneur Series: Bobak Azamian, MD (Tarsus)

What are the limitations and challenges of pursuing a career outside the traditional career path? How can physicians broaden their conception of what impact...


Episode 10

November 03, 2021 00:42:17
Episode Cover

10- Physician-Executive Series: Sachin H. Jain, MD (SCAN Group and Health Plan)

What is the mission of big corporations in the healthcare business? How is AI going to impact the drug development continuum in the next...


Episode 20

March 23, 2022 00:48:37
Episode Cover

20- Physician-Investor Series: David Kaufman, MD (Third Rock Ventures)

Is it important for MDs to consider taking a more prominent role in the process of developing and getting drugs to market, either on...